From a relatively poor prognosis to severe toxicity risks, patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and the clinicians caring for them face several treatment challenges. Joining Dr. Charles Turck to discuss those unmet needs—and perhaps even more importantly, how we can address them through expert guidance and emerging therapies—is Dr. Ryan Cassaday, Associate Professor in the Division of Hematology and Oncology at the University of Washington School of Medicine in Seattle.